Found 18 articles for: "Benzoyl Peroxide"
Efficacy and Safety of Clascoterone Cream 1% and Clindamycin 1.2%/Benzoyl Peroxide 5% Gel Treatment in Patients With Acne
June 2026 | Volume 25 | Issue 6 | Original Article | 537 | Copyright © June 2026
Background: Clascoterone cream 1% is a topical androgen receptor inhibitor approved to treat acne vulgaris in patients ≥12 years of age. The American Academy of Dermatology re...
Read MoreMalassezia Folliculitis Presentation, Diagnosis, and Treatment: A Review of "Fungal Acne"
May 2026 | Volume 25 | Issue 5 | Original Article | 427 | Copyright © May 2026
Background: Malassezia folliculitis (MF), commonly referred to as "fungal acne" is a dermatological condition caused by colonization of the commensal fungus Malassezia, which tur...
Read MoreTreatment of Confluent and Reticulated Papillomatosis Using Fixed-Dose Clindamycin phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel
May 2026 | Volume 25 | Issue 5 | Case Reports | 474 | Copyright © May 2026
Introduction: Confluent and reticulated papillomatosis (CARP) is a rare, non-systemic disease usually treated using oral antibiotics.Case Presentation:Read MoreBenzoyl Peroxide and Malignancy Risk: A Systematic Review and Meta-analysis of Over 4 Million Patients
May 2026 | Volume 25 | Issue 5 | Editorials | e43 | Copyright © May 2026
Assessing Cutibacterium Acnes Susceptibility With Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel Use: Six-Month Analysis
November 2025 | Volume 24 | Issue 11 | Original Article | 1106 | Copyright © November 2025
Background: The only approved triple-combination acne treatment – clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel - demonstrated efficacy/safety ...
Read MoreSafety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Truncal Acne
August 2025 | Volume 24 | Issue 8 | Original Article | 803 | Copyright © August 2025
Background: Truncal acne is underdiagnosed and undertreated, and it can lead to scarring and postinflammatory hyperpigmentation. However, applying topical treatments to larger sk...
Read MoreThe Impact on Acne Treatment Regimens if Benzoyl Peroxide-Containing Products are Removed From the Market
June 2025 | Volume 24 | Issue 6 | Features | 586 | Copyright © June 2025
Benzyl peroxide (BPO) has been an important component of many acne treatment regimens. However, an independent testing laboratory, Valisure, filed a Citizen’s Petition with the US Food and ...
Read MoreClindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% for Acne: Results From A 6-Month Open-Label Study
May 2025 | Volume 24 | Issue 5 | Original Article | 516 | Copyright © May 2025
Background: Treatment of acne may require many months of treatment before maximal benefits are observed, and acne sequelae (eg, scarring, dyspigmentation) can persist long a...
Read MoreTriple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and Adolescents
December 2024 | Volume 23 | Issue 12 | Original Article | 1049 | Copyright © December 2024
Background: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose triple-combination approved for acne (indicated in patients ...
Read MoreClindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey
November 2024 | Volume 23 | Issue 11 | Case Reports | 1017 | Copyright © November 2024
Introduction: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination formulation approved for acne treatmen...
Read MoreClindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis
October 2024 | Volume 23 | Issue 10 | Original Article | 873 | Copyright © October 2024
Background: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the only fixed-dose triple-combination treatment approved for acne. This post hoc analys...
Read MoreA 2.6% Benzoyl Peroxide AV Cleanser Specifically Designed for Sensitive Skin Offers Good Efficacy and Tolerability
September 2024 | Volume 23 | Issue 9 | Original Article | 764 | Copyright © September 2024
Background: Mild-to-moderate acne vulgaris (AV) is common among adults, and benzoyl peroxide (BPO) has a long history of efficacy in reducing AV lesions. The efficacy of BPO is compar...
Read MoreSentiment Analysis of EPSOLAY (Microencapsulated Benzoyl Peroxide 5%) on Reddit: Pre- and Post-FDA Approval
June 2024 | Volume 23 | Issue 6 | Editorials | e149 | Copyright © June 2024
A Salicylic Acid-Based Dermocosmetic is Effective as an Adjunct to Benzoyl Peroxide for Mild to Moderate Acne and as Monotherapy in Maintenance Post Benzoyl Peroxide
December 2023 | Volume 22 | Issue 12 | Original Article | 1172 | Copyright © December 2023
Background: A dermocosmetic (DC) containing salicylic acid, niacinamide, and thermal spring water has been developed for the management of mild to moderate acne.Sixty Years of Benzoyl Peroxide Use in Dermatology
January 2023 | Volume 22 | Issue 1 | Original Article | 54 | Copyright © January 2023
Background: Benzoyl peroxide (BPO) has been used extensively in industry and health care for more than a century and has been approved for the treatment of acne for over 60 years. Recently, BPO receiv...
Read MoreA Topical Combination Regimen of Benzoyl Peroxide and Retinol Moisturizer for Mild to Moderate Acne
December 2022 | Volume 21 | Issue 12 | Original Article | 1340 | Copyright © December 2022
Read MoreReview of Tretinoin-Benzoyl Peroxide in The Treatment of Acne Vulgaris
October 2022 | Volume 21 | Issue 10 | Original Article | 1098 | Copyright © October 2022
Background: Acne vulgaris has a multifactorial pathogenesis, and combination therapy is recommended in most patients. A tretinoin 0.1%/benzoyl peroxide 3% (Tret-BPO) cream which uses ...
Read MoreTolerability and Efficacy of Clindamycin/Tretinoin versus Adapalene/Benzoyl Peroxide in the Treatment of Acne Vulgaris
March 2021 | Volume 20 | Issue 3 | Original Article | 295 | Copyright © March 2021
Acne vulgaris is the most common dermatological disorder worldwide, causing significant physical and psychological morbidity. Topical combination therapy has shown superior efficacy compared to monoth...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
